(SCL) Stepan - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8585861003

Stock: Surfactants, Polyols, Polyester Resins, Phthalic Anhydride, Flavor Emulsifiers

Total Rating 50

Risk 91

Buy Signal -0.37

Specialty Chemicals » Specialty Chemicals
Age: 33.9y

Market Cap: 1,303m
Avg Trading Vol: 11.7M USD

ATR: 2.77%
Peers RS (IBD): 78.38

EPS (Earnings per Share)

EPS CAGR: -59.49%
EPS Trend: -70.9%

Last SUE: -1.30
Qual. Beats: 0

Revenue

Rev. CAGR: -0.87%
Rev. Trend: -63.4%

Last SUE: -0.13
Qual. Beats: 0

Dividends

Dividend Yield	3.01%
Yield on Cost 5y	1.36%
Yield CAGR 5y	5.53%
Payout Consistency	100.0%
Payout Ratio	84.2%

Risk 5d forecast
Volatility	33.1%
Relative Tail Risk	-4.59%

Reward TTM
Sharpe Ratio	0.14
Alpha	-10.85

Character TTM
Beta	0.942
Beta Downside	0.875

Drawdowns 3y
Max DD	59.73%
CAGR/Max DD	-0.25

Description: SCL Stepan January 18, 2026

Stepan Company (NYSE:SCL) manufactures specialty and intermediate chemicals across three segments-Surfactants, Polymers, and Specialty Products-serving global manufacturers in cleaning, construction, food, and pharmaceutical markets.

Key data points: FY2023 revenue was approximately $1.6 billion with an adjusted EBITDA margin near 12%; the Surfactants segment benefits from sustained consumer-hygiene spending, while the Polymers segment is closely linked to U.S. housing-starts trends, which have risen 4% YoY in Q4 2024. The Specialty Products line is gaining traction from the projected 6% CAGR in the global nutritional-supplements market.

For a deeper quantitative view of SCL’s valuation metrics, the ValueRay platform offers a concise dashboard worth checking.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income: 45.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -3.49 > 1.0
NWC/Revenue: 9.34% < 20% (prev 9.00%; Δ 0.34% < -1%)
CFO/TA 0.06 > 3% & CFO 156.2m > Net Income 45.2m
Net Debt (589.0m) to EBITDA (199.0m): 2.96 < 3
Current Ratio: 1.30 > 1.5 & < 3
Outstanding Shares: last quarter (22.9m) vs 12m ago -0.15% < -2%
Gross Margin: 11.94% > 18% (prev 0.13%; Δ 1181 % > 0.5%)
Asset Turnover: 95.08% > 50% (prev 90.60%; Δ 4.48% > 0%)
Interest Coverage Ratio: 3.21 > 6 (EBITDA TTM 199.0m / Interest Expense TTM 24.1m)

Altman Z'' 3.57

A: 0.09 (Total Current Assets 929.1m - Total Current Liabilities 713.9m) / Total Assets 2.43b
B: 0.53 (Retained Earnings 1.29b / Total Assets 2.43b)
C: 0.03 (EBIT TTM 77.2m / Avg Total Assets 2.42b)
D: 0.99 (Book Value of Equity 1.18b / Total Liabilities 1.19b)
Altman-Z'' Score: 3.57 = A

Beneish M -3.01

DSRI: 0.95 (Receivables 436.1m/434.1m, Revenue 2.30b/2.19b)
GMI: 1.08 (GM 11.94% / 12.89%)
AQI: 0.99 (AQ_t 0.09 / AQ_t-1 0.09)
SGI: 1.05 (Revenue 2.30b / 2.19b)
TATA: -0.05 (NI 45.2m - CFO 156.2m) / TA 2.43b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA

What is the price of SCL shares?

As of February 07, 2026, the stock is trading at USD 62.73 with a total of 99,145 shares traded.
Over the past week, the price has changed by +8.89%, over one month by +27.24%, over three months by +47.96% and over the past year by +3.12%.

Is SCL a buy, sell or hold?

Stepan has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold SCL.

StrongBuy: 0
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the SCL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	75	19.6%
Analysts Target Price	75	19.6%
ValueRay Target Price	64	2%

SCL Fundamental Data Overview February 02, 2026

P/E Trailing = 28.805
P/E Forward = 16.2075
P/S = 0.5656
P/B = 1.0341
P/EG = 4.34
Revenue TTM = 2.30b USD
EBIT TTM = 77.2m USD
EBITDA TTM = 199.0m USD
Long Term Debt = 357.1m USD (from longTermDebt, last quarter)
Short Term Debt = 298.4m USD (from shortTermDebt, last quarter)
Debt = 707.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 589.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.89b USD (1.30b + Debt 707.5m - CCE 118.5m)
Interest Coverage Ratio = 3.21 (Ebit TTM 77.2m / Interest Expense TTM 24.1m)
EV/FCF = 58.98x (Enterprise Value 1.89b / FCF TTM 32.1m)
FCF Yield = 1.70% (FCF TTM 32.1m / Enterprise Value 1.89b)
FCF Margin = 1.39% (FCF TTM 32.1m / Revenue TTM 2.30b)
Net Margin = 1.96% (Net Income TTM 45.2m / Revenue TTM 2.30b)
Gross Margin = 11.94% ((Revenue TTM 2.30b - Cost of Revenue TTM 2.03b) / Revenue TTM)
Gross Margin QoQ = 12.03% (prev 12.09%)
Tobins Q-Ratio = 0.78 (Enterprise Value 1.89b / Total Assets 2.43b)
Interest Expense / Debt = 1.36% (Interest Expense 9.61m / Debt 707.5m)
Taxrate = 34.37% (5.68m / 16.5m)
NOPAT = 50.6m (EBIT 77.2m * (1 - 34.37%))
Current Ratio = 1.30 (Total Current Assets 929.1m / Total Current Liabilities 713.9m)
Debt / Equity = 0.57 (Debt 707.5m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 2.96 (Net Debt 589.0m / EBITDA 199.0m)
Debt / FCF = 18.36 (Net Debt 589.0m / FCF TTM 32.1m)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.87% (Net Income 45.2m / Total Assets 2.43b)
RoE = 3.72% (Net Income TTM 45.2m / Total Stockholder Equity 1.21b)
RoCE = 4.91% (EBIT 77.2m / Capital Employed (Equity 1.21b + L.T.Debt 357.1m))
RoIC = 2.72% (NOPAT 50.6m / Invested Capital 1.86b)
WACC = 6.39% (E(1.30b)/V(2.01b) * Re(9.38%) + D(707.5m)/V(2.01b) * Rd(1.36%) * (1-Tc(0.34)))
Discount Rate = 9.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.21%
[DCF Debug] Terminal Value 80.08% ; FCFF base≈65.6m ; Y1≈48.1m ; Y5≈27.4m
Fair Price DCF = 6.67 (EV 739.8m - Net Debt 589.0m = Equity 150.8m / Shares 22.6m; r=6.39% [WACC]; 5y FCF grow -31.47% → 2.90% )
EPS Correlation: -70.87 | EPS CAGR: -59.49% | SUE: -1.30 | # QB: 0
Revenue Correlation: -63.41 | Revenue CAGR: -0.87% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.91 | Chg30d=-0.080 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=3.52 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+56.6% | Growth Revenue=+8.1%

Additional Sources for SCL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle